Kyverna Therapeutics, a late-stage biopharmaceutical company focused on cell therapies for autoimmune diseases, announced presentations at the H.C. Wainwright Nasdaq BioConnect Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. These events will feature management discussions and investor meetings, with live webcasts available on Kyverna's website. The company is advancing its lead CAR T-cell therapy, miv-cel, targeting B-cell-driven autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis, with ongoing clinical trials and regulatory submissions. These presentations aim to update investors on progress and future plans in developing innovative treatments for autoimmune conditions.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
